Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by lonc17on Oct 20, 2020 2:20pm
376 Views
Post# 31749062

Warrants

WarrantsA friendly reminder to those looking at the warrants.  The excercise price and the number of warrants required to purchase a single share have both been affected by an earlier reverse split. 

You need 9.5 warrants to purchase one share of ONC at $9.025 Canadian. 

So, whatever price the warrants are trading at needs to be multiplied by 9.5 to determine the true price.  They are no where near the bargain they appear to be.  Unless you are hoping to sell them to the next sucker.  

I hope this latest run is for real.  EVERY time that ONC has spiked in volume over the past three years it has been the result of boiler room activity on the part of managment to artifically raise the price to sell into the ATM.  Without news, there is no reason for this price spike and the massive new volume should send alarm signals to potential investors. 

ONC management can not be trusted.  Too bad, because the OV industry does have great potential.  
Bullboard Posts